NasdaqGS:GILDBiotechs
Gilead Sciences (GILD) Is Up 7.4% After FDA Expands Yescarta Lymphoma Label Restrictions Removed
In early February 2026, Kite, a Gilead company, reported that the FDA approved an update to Yescarta’s prescribing information, removing prior use limitations in patients with relapsed or refractory primary central nervous system lymphoma based on Phase 1 data from Dana-Farber Cancer Institute.
This change makes Yescarta the only CAR T-cell therapy for relapsed or refractory large B-cell lymphoma without such restrictions in PCNSL, addressing a cancer subset with a five-year survival rate of...